Literature DB >> 20433433

Different effects of low weight molecular heparin and unfractioned heparin on lipid profile and coagulation at haemodialysis patients.

Halima Resić1, Nihad Kukavica, Vahidin Sahović, Fahrudin Masnić.   

Abstract

Each haemodialysis treatment requires the application of anticoagulation medicines, which will prevent coagulation in extracorporal blood circulation. In this study we try to determine the quality of admitted anticoagulant and his effect on lipid profile on hemodialysis patients after twelve months. We were applying standard heparin and low weight molecular heparin (LWMH). During our study we was analyzed effect of anticoagulant therapy on lipid profile of hemodialysis patients. In that parameters was included triglycerides, cholesterol, lipoprotein fractions, complete blood count, Hgb, HCT; All of these parameters was analyzed in correlation with duration of hemodialysis treatment, sex and age of the patients. Our research was carried out as a prospective study, for the period of 12 months. In the study were included 60 patients (34M/26F), who were on chronic hemodialysis program. All patients were divided into two groups. The first group of patients was included 27 patients (15M/12F) who were treated with standard heparin. The second group was included 33 patients (19M/14F) treated with LWMH (enoxaparin). The average length of hemodialysis was 4.15 +/- 0.52 years. Each patient had a protocol in which is marked parameters such as flushing dialysator, creating fibrin-ring in vein and arterial dropper and the time it takes to stop the bleeding. In the results the average age amounted to 58.54 +/- 2.24 years. The average value of cholesterol in the blood was 5.38 +/- 2.26. Values of HDL-cholesterol in patients treated with LWMH were significantly lower (P<or=0.05) in the treated group compared to standard heparin. There were no significant statistical differences between both groups in relation to the level of LDL cholesterol in the blood. (p ns). LWMH had a better effect on the irrigation system and dialysator on both sex equally, compared with standard heparin. LWMH is in the female dialysis population has led to improvements in lipid profile. After the first six months of study in male patients treated with standard heparin in relation to the female part of the observed patients was significantly better anticoagulation effect in the first half of the study (1.85 +/- 0.05 compared to 2.09 +/- 0.10) (P<or=0.001). Average rating blood clots were statistically significant for standard heparin (p<or=0,001) with 1,86 at the beginning the value is fell to 1.41, while for LWMH with 1.85 at the beginning of the study amounted to 1.52 grade average. (P<or=0.05). The results of our study show that LWMH had a better rinsing effect of dialysis systems and dialysator in both sex equally, compared to standard unfractioned heparin. When the male part of the respondents in the first six months of standard heparin had a better evaluation of blood clots than women in the same group, and also better than the group on enoxaparin for both gender. LWMH in female dialysis population has led to improved lipid profiles. Patients treated with standard heparin had a statistically significant reduction in the rate of blood clots than patients who received enoxaparin (LWMH). Such differences were minimal, which can be interpreted by the fact that LWMH still derivative of the standard heparin.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20433433      PMCID: PMC5627715          DOI: 10.17305/bjbms.2010.2650

Source DB:  PubMed          Journal:  Bosn J Basic Med Sci        ISSN: 1512-8601            Impact factor:   3.363


  14 in total

1.  Apolipoprotein A-IV serum concentrations are elevated in patients with mild and moderate renal failure.

Authors:  Florian Kronenberg; Erich Kuen; Eberhard Ritz; Paul König; Günter Kraatz; Karl Lhotta; Johannes F E Mann; Gerhard A Müller; Ulrich Neyer; Werner Riegel; Peter Riegler; Vedat Schwenger; Arnold von Eckardstein
Journal:  J Am Soc Nephrol       Date:  2002-02       Impact factor: 10.121

Review 2.  The effect of fluvastatin on cardiac outcomes in patients with moderate to severe renal insufficiency: a pooled analysis of double-blind, randomized trials.

Authors:  Hallvard Holdaas; Christoph Wanner; Claudia Abletshauser; Claudio Gimpelewicz; Jonathan Isaacsohn
Journal:  Int J Cardiol       Date:  2006-08-04       Impact factor: 4.164

3.  Identification of scavenger receptor SR-BI as a high density lipoprotein receptor.

Authors:  S Acton; A Rigotti; K T Landschulz; S Xu; H H Hobbs; M Krieger
Journal:  Science       Date:  1996-01-26       Impact factor: 47.728

4.  Remnant-like particle (RLP) cholesterol is an independent cardiovascular disease risk factor in women: results from the Framingham Heart Study.

Authors:  J R McNamara; P K Shah; K Nakajima; L A Cupples; P W Wilson; J M Ordovas; E J Schaefer
Journal:  Atherosclerosis       Date:  2001-01       Impact factor: 5.162

5.  Lipoprotein abnormalities in hyperlipidemic and normolipidemic men on hemodialysis with chronic renal failure.

Authors:  M Sentí; R Romero; J Pedro-Botet; A Pelegrí; X Nogués; J Rubiés-Prat
Journal:  Kidney Int       Date:  1992-05       Impact factor: 10.612

Review 6.  Pathogenesis of dyslipoproteinemia in renal insufficiency: the role of lipoprotein lipase and hepatic lipase.

Authors:  M Arnadóttir
Journal:  Scand J Clin Lab Invest       Date:  1997-02       Impact factor: 1.713

7.  Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis.

Authors:  Christoph Wanner; Vera Krane; Winfried März; Manfred Olschewski; Johannes F E Mann; Günther Ruf; Eberhard Ritz
Journal:  N Engl J Med       Date:  2005-07-21       Impact factor: 91.245

8.  Long-term fluvastatin reduces the hazardous effect of renal impairment on four-year atherosclerotic outcomes (a LIPS substudy).

Authors:  Pedro A Lemos; Patrick W Serruys; Pim de Feyter; Nestor F Mercado; Dick Goedhart; Francesco Saia; Chourmouzios A Arampatzis; Paulo R Soares; Marco Ciccone; Massimo Arquati; Michele Cortellaro; Wolfgang Rutsch; Victor Legrand
Journal:  Am J Cardiol       Date:  2005-02-15       Impact factor: 2.778

9.  Gemfibrozil for secondary prevention of cardiovascular events in mild to moderate chronic renal insufficiency.

Authors:  Marcello Tonelli; Dorothea Collins; Sander Robins; Hanna Bloomfield; Gary C Curhan
Journal:  Kidney Int       Date:  2004-09       Impact factor: 10.612

Review 10.  Effect of pravastatin on cardiovascular events in people with chronic kidney disease.

Authors:  Marcello Tonelli; Chris Isles; Gary C Curhan; Andrew Tonkin; Marc A Pfeffer; James Shepherd; Frank M Sacks; Curt Furberg; Stuart M Cobbe; John Simes; Timothy Craven; Malcolm West
Journal:  Circulation       Date:  2004-09-13       Impact factor: 29.690

View more
  1 in total

1.  Tinzaparin provides lower lipid profiles in maintenance hemodialysis patients: a cross-sectional observational study.

Authors:  Ming-Hsien Tsai; Yu-Wei Fang; Jyh-Gang Leu
Journal:  ScientificWorldJournal       Date:  2014-11-13
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.